Brooks O'Neil

Q: What is Brooks O'Neil's success rate?

Brooks O'Neil currently has a success rate of 90.26490066225165.

Q: What is the average return of Brooks O'Neil's calls?

Their stock ratings have generated an average return of 23.315994185711265.

Lake Street | Healthcare

Brooks O'Neil is an analyst from Lake Street specializing in the Healthcare sector. Ranked #1204 out of 4655 analysts, they have issued 7 stock ratings with a success rate of 90.26% and an average return of 23.32%.

With 7 ratings to date, Brooks O'Neil is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 90.26% and an average return of 23.32%, highlighting promising potential as their track record develops further.

#1204

Out of 4655

Total Ratings

+90.26%

Success Rate

+23.32%

Average Return

Recent Ratings Analysis

LFVN

Hold

May 07, 2026

Target

$5.00

Current

$5.15

Performance

2.59%

Brooks O'Neil rated LFVN as Hold on May 07, 2026, setting a price target of 5. The Hold stance appears justified, as shares hovered around 5.15 with a 2.59% move.

MDXG

Buy

Jan 20, 2026

Target

$10.00

Current

$3.54

Performance

-34.32%

On Jan 20, 2026, MDXG was given a Buy rating by Brooks O'Neil, with a target price of 10. Despite the Buy call, shares fell from 3.54 to 3.54, challenging the optimistic stance.

LFMD

Buy

Nov 18, 2025

Target

$8.00

Current

$4.28

Performance

4.65%

LFMD received a Buy rating from Brooks O'Neil on Nov 18, 2025, aiming for 8. Price action was muted, as shares hovered around 4.28 despite the bullish outlook.

TNDM

Hold

Aug 11, 2025

Target

$12.00

Current

$14.69

Performance

45.16%

On Aug 11, 2025, Brooks O'Neil published a Hold outlook on TNDM, with a target of 12. The Hold call missed some of the bullish momentum as shares advanced toward 12.

RCEL

Buy

Aug 11, 2025

Target

$8.00

Current

$4.38

Performance

-8.94%

Brooks O'Neil on Aug 11, 2025 assigned RCEL a Buy rating, with a price target of 8. The call has struggled to gain traction, with shares losing 8.94%.

SRDX

Buy

Mar 07, 2025

Target

$43.00

Current

$42.98

Performance

46.34%

On Mar 07, 2025, Brooks O'Neil reaffirmed SRDX with a Buy rating, targeting 43. The recommendation was supported by strong follow-through as the stock rose from 42.98 to 42.98.

LMAT

Buy

Feb 28, 2025

Target

$110.00

Current

$97.22

Performance

5.85%

LMAT was rated Buy by Brooks O'Neil on Feb 28, 2025, with a price objective of 110. A bullish response from the market helped close the gap of 12.78 to the target.

BBNX

Buy

Feb 24, 2025

Target

$30.00

Current

$9.82

Performance

-52.33%

On Feb 24, 2025, Brooks O'Neil initiated coverage on BBNX with a Buy rating and target of 30. The Buy call has yet to be validated as shares remain 20.18 away from the target.

SMLR

Buy

Jan 24, 2025

Target

$71.00

Current

$20.33

Performance

-63.34%

Brooks O'Neil issued a Buy recommendation for SMLR on Jan 24, 2025, price target set at 71. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

MODV

Buy

Jan 13, 2025

Target

$10.00

Current

$0.43

Performance

-93.51%

On Jan 13, 2025, MODV was evaluated by Brooks O'Neil, who gave a Buy rating and target of 10. Investors saw limited payoff as shares fell short of the 10 target.

HROW

Buy

Oct 04, 2024

Target

$55.00

Current

$29.03

Performance

-42.37%

Brooks O'Neil rated HROW as Buy on Oct 04, 2024, setting a price target of 55. The stock has underperformed, dropping 42.37% despite the bullish target of 55.

ATEC

Buy

Sep 03, 2024

Target

$18.00

Current

$7.74

Performance

13.82%

On Sep 03, 2024, ATEC was given a Buy rating by Brooks O'Neil, with a target price of 18. The stock rallied 13.82% after the rating, narrowing the gap to the target of 18 and validating the bullish stance.

AUGX

Hold

Jul 22, 2024

Target

—

Current

$2.35

Performance

3.30%

AUGX received a Hold rating from Brooks O'Neil on Jul 22, 2024, aiming for null. Shares remained flat at 2.345, aligning with the neutral rating.

ORGO

Buy

Jun 28, 2024

Target

$5.00

Current

$2.41

Performance

-13.93%

On Jun 28, 2024, Brooks O'Neil published a Buy outlook on ORGO, with a target of 5. Market action contradicted the Buy thesis, as shares slipped to 2.41.

Frequency Asked Questions

Who is Brooks O'Neil?

Brooks O'Neil is an analyst from Lake Street specializing in the Healthcare sector.

What is Brooks O'Neil's success rate?

Brooks O'Neil currently has a success rate of +90.26%.

How many ratings has Brooks O'Neil issued?

Brooks O'Neil has issued 7 stock ratings so far.

What is the average return of Brooks O'Neil's calls?

Their stock ratings have generated an average return of +23.32%.

What is Brooks O'Neil's ranking?

Brooks O'Neil is ranked #1204 out of 4655 analysts.

What types of ratings does Brooks O'Neil give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Brooks O'Neil?

You can follow Brooks O'Neil by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Brooks O'Neil?

Their latest rating was a Hold on LFVN issued on 2026-05-07.